Comparison
CJC-1295 vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
no data
2179963-22-7
Molecular weight
3647.3 g/mol
4727 g/mol
Half-life
144 h
168 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
2